Abstract:Introduction c-Myc plays a central role in cellular proliferation, differentiation, and apoptosis. Therefore its deregulation represents a powerful trigger of tumorigenesis, particularly in colorectal cancer (CRC). It has been shown that the MEK/ERK pathway phosphorylates c-Myc on serine 62, which stabilises c-Myc by preventing ubiquitin/proteasomal degradation. We recently reported that MEK/ERK inhibition is counteracted by over-activation of p38α MAPK. Here, we identified cellular mechanisms that lead to c-Myc deregulation, which is a crucial issue for improving CRC treatment and survival. Material and methods The cross-talk between p38α and ERK was assessed in CRC cell lines and in APCMin/+ mice, a murine model of familial adenomatous polyposis. To this aim, animals were treated with the p38α inhibitor 4-(4-Fluorophenyl)−2-(4-hydroxyphenyl)−5-(4-pyridyl)−1H-imidazole (SB202190) alone or in combination with the MEK1 inhibitor N-[(2R)−2,3-Dihydroxypropoxy]−3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide (PD0325901). In order to evaluate the role of p38α and ERK in c-Myc regulation, we used pharmacological inhibitors of these two kinases alone or in combination with inhibitors of the transcriptional mechanism, translational process and proteasome in CRC cell lines. Moreover, the function of p38α and ERK in Myc stabilisation was assessed by genetic ablation. Results and discussions Here we show that concomitant inhibition of the p38α and MEK/ERK pathways significantly increases the survival of APCMin/+ mice in which tumorigenesis is driven by c-Myc deregulation. Genetic ablation of p38α and ERK revealed that these two MAPKs do not regulate c-Myc expression, nor do they affect c-Myc protein translational process. We found that p38α and ERK collaborate in c-Myc stabilisation by inhibiting its proteasomal degradation in CRC cell lines. These results were also confirmed by using the p38α and ERK pharmacological inhibitors LY2228820 (Ralimetinib) and GSK1120212 (Mekinist), respectively, which are currently in clinical trials for inflammatory diseases and cancer. Conclusion Since c-MYC supports the processes required for normal growth and homeostasis, its ablation is less attractive than modulation of its expression or function. Our results confirmed the essential role of the MAPK/c-Myc axis in intestinal tumorigenesis regulation, suggesting MAPK manipulation as a potential therapeutic approach to counteract c-Myc dependent carcinogenesis.

Uncoupling p38α nuclear and cytoplasmic functions and identification of two p38α phosphorylation sites on β-catenin: implications for the Wnt signaling pathway in CRC models

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

To Wnt or Lose: the Missing Non-Coding Linc in Colorectal Cancer

PO-006 The MAPK/c-Myc axis in CRC: new pathogenic mechanisms and therapeutic approaches

Targeting p38γ to inhibit human colorectal cancer cell progression.

An MST4‐p β ‐Catenin Thr40 Signaling Axis Controls Intestinal Stem Cell and Tumorigenesis

An MST4-pβ-CateninThr40 Signaling Axis Controls Intestinal Stem Cell and Tumorigenesis.

An MST4-p-Catenin<SUP>Thr40</SUP> Signaling Axis Controls Intestinal Stem Cell and Tumorigenesis

P38α Mitogen-Activated Protein Kinase is a Druggable Target in Pancreatic Adenocarcinoma

p38-regulated FOXC1 stability is required for colorectal cancer metastasis.

Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer

Protein Kinase P38α Signaling in Dendritic Cells Regulates Colon Inflammation and Tumorigenesis

WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer

Phosphorylation of PPDPF via IL6‐JAK2 activates the Wnt/β‐catenin pathway in colorectal cancer

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer

USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potential

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma

Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer

Analysis of tumor-associated AXIN1 missense mutations identifies variants that activate β-catenin signaling

A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer

Restraining Wnt activation and intestinal tumorigenesis by a Rab35 dependent GTPase relay